Nanoscope Therapeutics announced publication of a new peer-reviewed observational study in Documenta Ophthalmologica¹ that focuses on functional vision assessment in patients with retinal disease and severe vision loss. According to the company, the study supports the use of tools that can better capture meaningful visual function and patient experience in standard retina practice.

The prospective observational study included 35 participants, including 25 with severe vision loss due to retinitis pigmentosa and 10 with normal vision. The company said the findings provide supportive evidence for the reliability and validity of the Multi-luminance Shape Discrimination Test as a performance-based measure of visual ability in individuals with severe visual impairment.

Nanoscope noted that, in addition to BCVA as the primary endpoint, its phase 2b/3 RESTORE trial of MCO-010 also evaluated functional vision with the Multi-luminance Shape Discrimination Test as a secondary endpoint. At week 52, the company reported that most MCO-010-treated patients improved by 2 or more luminance levels on the test, which it described as clinically meaningful.

The company said the publication adds to ongoing efforts to define meaningful measures of treatment benefit in patients with severe retinal degeneration and vision impairment. Nanoscope also stated that MCO-010 is being developed as a one-time, in-office, disease-agnostic optogenetic therapy platform for retinal degenerative disease.

References

1. Emanuelli A, Bakall B, Lam BL, et al. Validation of a novel multi-luminance shape discrimination test for assessment of functional vision. Doc Ophthalmol. 2026;148(3):[Epub ahead of print].